130 related articles for article (PubMed ID: 8391862)
1. Susceptibility of anaerobes in phase 3 clinical studies of piperacillin/tazobactam.
Jacobus NV; Immermann FW; Gupte JM; Testa RT
Clin Infect Dis; 1993 Jun; 16 Suppl 4():S344-8. PubMed ID: 8391862
[No Abstract] [Full Text] [Related]
2. Comparative susceptibility profile of piperacillin/tazobactam against anaerobic bacteria.
Appelbaum PC
J Antimicrob Chemother; 1993 Jan; 31 Suppl A():29-38. PubMed ID: 8383654
[TBL] [Abstract][Full Text] [Related]
3. Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
Tellado J; Woods GL; Gesser R; McCarroll K; Teppler H
Surg Infect (Larchmt); 2002; 3(4):303-14. PubMed ID: 12697078
[TBL] [Abstract][Full Text] [Related]
4. The sensitivity of clinical isolates of anaerobic species to piperacillin-tazobactam and other antimicrobial agents.
Namavar F; Severin WP; Stobberingh E; Smeets T; MacLaren DM
J Antimicrob Chemother; 1994 Sep; 34(3):415-9. PubMed ID: 7829416
[No Abstract] [Full Text] [Related]
5. Susceptibility survey of piperacillin alone and in the presence of tazobactam.
Acar JF; Goldstein FW; Kitzis MD
J Antimicrob Chemother; 1993 Jan; 31 Suppl A():23-8. PubMed ID: 8383653
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of ceftriaxone combined with tazobactam against anaerobic bacteria.
Wüst J; Hardegger U
Eur J Clin Microbiol Infect Dis; 1994 Feb; 13(2):177-81. PubMed ID: 8013494
[TBL] [Abstract][Full Text] [Related]
7. [Fundamental and clinical studies on beta-lactamase inhibitors].
Niki Y
Nihon Rinsho; 2001 Apr; 59(4):771-6. PubMed ID: 11305004
[TBL] [Abstract][Full Text] [Related]
8. Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
Schoonover LL; Occhipinti DJ; Rodvold KA; Danziger LH
Ann Pharmacother; 1995 May; 29(5):501-14. PubMed ID: 7655135
[TBL] [Abstract][Full Text] [Related]
9. Effect of pH on antibiotics used to treat anaerobic infection.
Winstanley TG; Wilcox MH; Spencer RC
J Antimicrob Chemother; 1992 May; 29(5):594-5. PubMed ID: 1320606
[No Abstract] [Full Text] [Related]
10. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.
Eklund AE; Nord CE
J Antimicrob Chemother; 1993 Jan; 31 Suppl A():79-85. PubMed ID: 8383657
[TBL] [Abstract][Full Text] [Related]
11. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
[TBL] [Abstract][Full Text] [Related]
12. [Initial empirical antimicrobial therapy with piperacillin/tazobactam in intra-abdominal infections due to perforation of the large intestine and rectum and in postoperative complications after resection of the large intestine and rectum].
Vyhnánek F; Faltýn J; Lochmann O
Rozhl Chir; 2002 Dec; 81(12):617-21. PubMed ID: 12666475
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections.
Sörgel F; Kinzig M
Eur J Surg Suppl; 1994; (573):39-44. PubMed ID: 7524794
[TBL] [Abstract][Full Text] [Related]
14. Piperacillin/Tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery.
Maltezou HC; Nikolaidis P; Lebesii E; Dimitriou L; Androulakakis E; Kafetzis DA
Eur J Clin Microbiol Infect Dis; 2001 Sep; 20(9):643-6. PubMed ID: 11714046
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of in vitro susceptibility of hospital bacterial isolates to piperacillin and tazocin (piperacillin/tazobactam].
Birawska I; Fuchs J; Szulakowska E
Med Dosw Mikrobiol; 1998; 50(1-2):41-6. PubMed ID: 9857612
[TBL] [Abstract][Full Text] [Related]
16. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam.
Appelbaum PC; Spangler SK; Jacobs MR
J Antimicrob Chemother; 1993 Aug; 32(2):223-31. PubMed ID: 8226424
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of 2 administration protocols (continuous or discontinuous) of a time-dependent antibiotic, Tazocin].
Pédeboscq S; Dubau B; Frappier S; Hernandez V; Veyssières D; Winnock S; Pometan JP
Pathol Biol (Paris); 2001 Sep; 49(7):540-7. PubMed ID: 11642016
[TBL] [Abstract][Full Text] [Related]
18. The activity of piperacillin/tazobactam against clinical isolates collected in 20 UK centres and the design of a disc test for susceptibility testing.
Reeves DS; Holt HA; Bywater MJ; MacGowan AP
J Antimicrob Chemother; 1993 Jul; 32(1):51-61. PubMed ID: 8226417
[TBL] [Abstract][Full Text] [Related]
19. Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues.
Incavo SJ; Ronchetti PJ; Choi JH; Wu H; Kinzig M; Sörgel F
Antimicrob Agents Chemother; 1994 Apr; 38(4):905-7. PubMed ID: 8031071
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activities of piperacillin alone and in combination with tazobactam against beta-lactamase-producing bacteria.
Chang SC; Hsu LY; Luh KT; Hsieh WC
J Formos Med Assoc; 1991 Oct; 90(10):947-52. PubMed ID: 1685175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
